Data completeness
0/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TACARYL (methdilazine) is an oral chewable tablet antihistamine developed by Bristol Myers Squibb. The specific indications and mechanism of action are not documented in current data, but methdilazine is a first-generation H1-receptor antagonist historically used for allergic conditions and pruritus. The product is in pre-launch stage, indicating early commercial development.
Pre-Launch
Pre-launch phase indicates early-stage commercial infrastructure building; team expansion expected in marketing, market access, and sales preparation roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TACARYL is a pre-launch asset with no current linked job openings, reflecting its early stage. Career opportunities will emerge post-approval as the brand builds commercial infrastructure, particularly in launch management, market access, and field team roles.
Brand ManagerMarket Access Manager
Worked on TACARYL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.